{"id":"e7820-plus-cetuximab","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Integrin α2 and EGFR","explanation":"E7820 is a small molecule that suppresses integrin α2 subunit expression, which may inhibit tumor angiogenesis and metastasis. Cetuximab is a monoclonal antibody that binds to epidermal growth factor receptor (EGFR), blocking downstream signaling pathways involved in tumor cell proliferation and survival.","oneSentence":"E7820 inhibits integrin α2 expression while cetuximab blocks EGFR signaling, providing dual anti-tumor activity."},"_scrapedAt":"2026-03-28T02:36:20.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123252,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"bevacizumab","brand":"Avastin","company":"Genentech/Roche","rationale":"Anti-angiogenic therapy combined with EGFR inhibitors in colorectal cancer"},{"name":"panitumumab","brand":"Vectibix","company":"Amgen","rationale":"EGFR-targeting monoclonal antibody for colorectal cancer"},{"name":"regorafenib","brand":"Stivarga","company":"Bayer","rationale":"Multi-kinase inhibitor for advanced colorectal cancer"}],"description":"E7820 plus cetuximab is an investigational combination therapy developed by Eisai Inc. for cancer treatment. E7820 is combined with cetuximab, an EGFR-targeting monoclonal antibody, and is being evaluated in Phase 2 clinical trials for potential oncology applications.","indications":{"approved":[{"status":"investigational","condition":"Colorectal cancer","patientPopulation":"Adult patients with advanced disease"}]},"trialDetails":[{"nctId":"NCT00309179","phase":"PHASE2","title":"A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-09-24","conditions":"Advanced Colorectal Cancer","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"E7820 plus cetuximab","genericName":"E7820 plus cetuximab","companyName":"Eisai Inc.","companyId":"eisai","firstApprovalDate":"","aiSummary":"E7820 is an inhibitor of the epidermal growth factor receptor, and it is being studied in combination with cetuximab, an antibody that also targets the epidermal growth factor receptor, for the treatment of advanced colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}